Czech National Bank Increases Stake in Medtronic PLC $MDT

Czech National Bank boosted its stake in shares of Medtronic PLC (NYSE:MDT) by 3.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 338,206 shares of the medical technology company’s stock after purchasing an additional 12,791 shares during the period. Czech National Bank’s holdings in Medtronic were worth $32,488,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of MDT. Cullen Investment Group LTD. lifted its stake in shares of Medtronic by 12.2% during the fourth quarter. Cullen Investment Group LTD. now owns 104,479 shares of the medical technology company’s stock worth $10,191,000 after buying an additional 11,375 shares during the period. Optivise Advisory Services LLC grew its holdings in shares of Medtronic by 31.5% during the fourth quarter. Optivise Advisory Services LLC now owns 2,873 shares of the medical technology company’s stock valued at $276,000 after buying an additional 689 shares during the last quarter. Salvus Wealth Management LLC increased its position in shares of Medtronic by 1.4% in the 4th quarter. Salvus Wealth Management LLC now owns 8,197 shares of the medical technology company’s stock valued at $787,000 after acquiring an additional 110 shares during the period. Balefire LLC raised its stake in Medtronic by 18.2% in the 4th quarter. Balefire LLC now owns 23,598 shares of the medical technology company’s stock worth $2,267,000 after acquiring an additional 3,640 shares during the last quarter. Finally, Thrive Wealth Management LLC raised its stake in Medtronic by 3.6% in the 4th quarter. Thrive Wealth Management LLC now owns 5,569 shares of the medical technology company’s stock worth $535,000 after acquiring an additional 193 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on MDT. Robert W. Baird dropped their price target on Medtronic from $103.00 to $100.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 18th. Wells Fargo & Company began coverage on Medtronic in a research note on Friday, January 30th. They issued an “overweight” rating and a $114.00 price objective for the company. Mizuho raised Medtronic to a “strong-buy” rating in a report on Wednesday, February 18th. Piper Sandler reiterated a “neutral” rating on shares of Medtronic in a research report on Monday, January 5th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $120.00 price target on shares of Medtronic in a report on Tuesday, March 10th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $110.74.

Medtronic Price Performance

Shares of MDT opened at $87.84 on Thursday. The business’s 50-day moving average is $96.22 and its two-hundred day moving average is $96.58. The company has a market capitalization of $112.77 billion, a P/E ratio of 24.47, a P/E/G ratio of 2.22 and a beta of 0.71. Medtronic PLC has a fifty-two week low of $79.55 and a fifty-two week high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.02. The business had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts predict that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be given a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 3.2%. The ex-dividend date is Friday, March 27th. Medtronic’s dividend payout ratio is currently 79.11%.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Distribution deal expands Medtronic’s chronic‑pain portfolio — Medtronic agreed to distribute Merit Medical’s FDA‑cleared ViaVerte basivertebral nerve ablation (BVNA) system, adding a minimally invasive, implant‑free option for chronic vertebrogenic low‑back pain and broadening its interventional pain offering. This can support revenue growth in a high‑demand pain segment. Medtronic and Merit Medical Systems enter into agreement
• Positive Sentiment: FDA expands indication for OmniaSecure lead — The FDA cleared an expanded indication that allows placement of Medtronic’s OmniaSecure defibrillation lead in the left bundle branch area for conduction‑system pacing, strengthening its electrophysiology product lineup and supporting growth in cardiac rhythm management. Medtronic Announces FDA Approval for Expanded Indication of OmniaSecure
• Positive Sentiment: Spin‑off of diabetes unit remains a strategic catalyst — Coverage and commentary note Medtronic’s planned diabetes‑unit spin‑off later this year; separating the high‑growth diabetes business may unlock valuation for both the diabetes standalone and the remaining higher‑margin device franchises. This is a medium‑term positive for investor sentiment. Medtronic to Spin-Off High-Growth Diabetes Unit
• Neutral Sentiment: Analyst sentiment and “undervalued” mentions — Recent writeups and analyst coverage label MDT a moderate buy/undervalued blue‑chip, which can support steadier investor interest but is unlikely to trigger large moves absent fundamentals. Medtronic Given Consensus Rating of “Moderate Buy”
• Negative Sentiment: Guidance cut and charge tied to MiniMed approvals — Medtronic lowered its 2026 earnings outlook, citing a private‑equity related charge connected to MiniMed approval updates. That revision is a direct near‑term earnings headwind and a clear negative on short‑term sentiment. Medtronic cuts 2026 guidance on private equity charge related to MiniMed approval

Insider Buying and Selling

In other news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This trade represents a 61.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.26% of the company’s stock.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).